We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$310M
AUM Growth
+$8.93M
Cap. Flow
+$4.99M
Cap. Flow %
1.61%
Top 10 Hldgs %
58.2%
Holding
58
New
5
Increased
12
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$13.4M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.82M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.27M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.06M
5
XLRN
Acceleron Pharma
XLRN
+$5.28M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.1M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$9.04M
3
ZGNX
Zogenix, Inc.
ZGNX
+$6.17M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
51
DELISTED
Esperion Therapeutics
ESPR
$353K 0.11%
9,500
– –
ZEAL
52
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$210K 0.07%
5,653
– –
ANAB icon
53
AnaptysBio
ANAB
$1.7B
$148K 0.05%
10,000
– –
ENTA icon
54
Enanta Pharmaceuticals
ENTA
$402M
– –
-46,500
Closed -$2.28M
SAGE
55
DELISTED
Sage Therapeutics
SAGE
– –
-37,600
Closed -$1.57M
MNTA
56
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-27,000
Closed -$970K
PRNB
57
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-23,100
Closed -$1.3M
ZGNX
58
DELISTED
Zogenix, Inc.
ZGNX
– –
-236,832
Closed -$6.17M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2020 Portfolio in Review

As of Q3 2020, International Biotechnology Trust held 58 positions worth $310M, up 3% from $301M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

International Biotechnology Trust's Q3 2020 filing shows 5 new, 12 increased, 7 reduced and 5 closed positions. Its largest new stake was Iovance Biotherapeutics: 145,000 shares worth $4.77M. The largest sale was Immunomedics Inc, an estimated $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2020 buy was Iovance Biotherapeutics: 145,000 shares worth $4.77M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q3 2020, an estimated $13.4M increase.
  • International Biotechnology Trust's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $20.1M.
  • International Biotechnology Trust fully exited Zogenix, Inc. in Q3 2020, selling an estimated $6.17M.
  • International Biotechnology Trust's ten largest holdings make up 58% of its $310M portfolio in Q3 2020.
  • International Biotechnology Trust opened 5 new positions and closed 5 in Q3 2020.
  • International Biotechnology Trust's portfolio value rose 3% quarter-over-quarter to $310M.

Based on International Biotechnology Trust's 13F filing for Q3 2020, filed 1 Dec 2020.